Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease

Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease

BackgroundParkinson’s disease (PD) is caused by the progressive loss of dopaminergic neurons in the substantia nigra. Neuroinflammation is considered a key factor contributing to the pathophysiology of PD. Current gold-standard therapies for PD provide only symptomatic relief without slowing disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayam Ali AlRasheed, Mostafa M. Bahaa, Thanaa A. Elmasry, Eman I. Elberri, Fedaa A. Kotkata, Ramy M. El Sabaa, Yasmine M. Elmorsi, Mostafa M. Kamel, Walaa A. Negm, Amir O. Hamouda, Khlood Mohammad Aldossary, Muhammed M. Salahuddin, Mohamed Yasser, Mamdouh Eldesouqui, Manal A. Hamouda, Nashwa Eltantawy, Mirna E. Elawady, Mahmoud S. Abdallah
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
Parkinson disease
metformin
neuro-inflammation
α-synuclein
TLR-4
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1497261/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1497261/full

Similar Items